Gilead Sciences Buys Calistoga Pharmaceuticals
Foster City-based Gilead Sciences said today that it is acquiring Calistoga Pharmaceuticals, a Seattle developer of inflammatory, autoimmune, and cancer drugs. Gilead will pay $375M plus up to $225M in earnout for Calistoga. Calistoga was venture backed by Alta Partners, Amgen Ventures, Frazier Healthcare Ventures, Latterell Venture Partners, Lilly Bioventures, Quogue Capital, Three Arch Partners, and others.
posted on Tuesday, February 22, 2011
Related companies:
Gilead Sciences
Related stories:
> Gilead Buys Myogen For $2.5B
> PayPal Buys Fraud Sciences Ltd. For $169M
> Anthera Pharmaceuticals Raises $19M
> APT Pharmaceuticals Adds On $22M
> Clarus Ventures Names New Partner
silicontap.com Home